- Home
- CGC vs BBOT Comparison
CGC vs BBOT Comparison
Compare CGC & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGC | BBOT |
|---|---|---|
| Founded | N/A | 2016 |
| Country | Canada | United States |
| Employees | 1128 | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 389.2M | 442.6M |
| IPO Year | 2023 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CGC | BBOT |
|---|---|---|
| Price | $0.93 | $4.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | ★ 3.1M | 545.3K |
| Earning Date | 05-29-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 84.17 | ★ 99.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,759,000.00 | N/A |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $15.68 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.84 | $4.90 |
| 52 Week High | $2.38 | $14.87 |
Technical Indicators
Market Signals| Indicator | CGC | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 18.58 |
| Support Level | $0.91 | N/A |
| Resistance Level | $1.15 | $9.53 |
| Average True Range (ATR) | 0.03 | 0.65 |
| MACD | -0.01 | -0.50 |
| Stochastic Oscillator | 3.54 | 3.37 |
Price Performance
Historical ComparisonAbout CGC Canopy Growth Corporation
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.